1 month AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales RiseZacks
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
XAngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
X